Global Manmade Version of Somatostatin Supply, Demand and Key Producers, 2024-2030

Description

The manmade version of somatostatin refers to synthetic analogues of the naturally occurring hormone somatostatin, designed to replicate its biological effects in the body. These synthetic versions, such as octreotide and lanreotide, are engineered to have enhanced stability, prolonged action, and improved pharmacokinetic profiles compared to natural somatostatin. They are primarily used in medical applications to inhibit the secretion of various hormones, making them effective treatments for conditions like acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

The global Manmade Version of Somatostatin market size is expected to reach $ 10700 million by 2030, rising at a market growth of 6.7% CAGR during the forecast period (2024-2030).

The market for manmade versions of somatostatin, particularly synthetic analogues like octreotide and lanreotide, is experiencing steady growth, primarily driven by the increasing prevalence of hormone-related disorders such as acromegaly and neuroendocrine tumors.

Recent advancements in formulation technology have further boosted the market for these synthetic analogues. Long-acting formulations allow for less frequent dosing, improving patient compliance and convenience. This shift towards sustained-release options has made treatment regimens easier to manage, leading to greater acceptance among both patients and healthcare providers. Additionally, ongoing research into new indications and combinations with other therapies is expanding the therapeutic potential of manmade somatostatin analogues, enhancing their market appeal.

Moreover, the growing trend towards personalized medicine is influencing the adoption of manmade somatostatin analogues. Healthcare providers are increasingly focusing on tailoring treatments to individual patient needs, making these targeted therapies particularly valuable. As clinical guidelines evolve and integrate these analogues into broader treatment strategies, the market is expected to continue expanding, supported by an increasing range of indications and ongoing innovations in drug development.

This report studies the global Manmade Version of Somatostatin production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Manmade Version of Somatostatin and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Manmade Version of Somatostatin that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Manmade Version of Somatostatin total production and demand, 2019-2030, (K Units)
Global Manmade Version of Somatostatin total production value, 2019-2030, (USD Million)
Global Manmade Version of Somatostatin production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units), (based on production site)
Global Manmade Version of Somatostatin consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Manmade Version of Somatostatin domestic production, consumption, key domestic manufacturers and share
Global Manmade Version of Somatostatin production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Manmade Version of Somatostatin production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Manmade Version of Somatostatin production by Application, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
This report profiles key players in the global Manmade Version of Somatostatin market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Ipsen, Recordati Rare Diseases, Chiesi Farmaceutici S.p.A, Advanz Pharma, Cipla, Teva, Gland Pharma, Heritage Pharmaceuticals, Sagent Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Manmade Version of Somatostatin market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Manmade Version of Somatostatin Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Manmade Version of Somatostatin Market, Segmentation by Type:
    Octreotide
    Lanreotide
    Pasireotide
    Other

Global Manmade Version of Somatostatin Market, Segmentation by Application:
    Neuroendocrine Tumors
    Acromegaly
    Cushing Syndrome
    Other

Companies Profiled:
    Novartis
    Ipsen
    Recordati Rare Diseases
    Chiesi Farmaceutici S.p.A
    Advanz Pharma
    Cipla
    Teva
    Gland Pharma
    Heritage Pharmaceuticals
    Sagent Pharmaceuticals
    Sun Pharmaceutical
    Fresenius Kabi
    Mylan
    West-Ward Pharmaceuticals
    Suzhou Tianma Pharmaceutical
    Sihuan Pharmaceutical
    Chengdu Tiantaishan pharmaceutical
    Hybio Pharmaceutical
    Hainan Shuangcheng Pharmaceuticals

Key Questions Answered:
1. How big is the global Manmade Version of Somatostatin market?
2. What is the demand of the global Manmade Version of Somatostatin market?
3. What is the year over year growth of the global Manmade Version of Somatostatin market?
4. What is the production and production value of the global Manmade Version of Somatostatin market?
5. Who are the key producers in the global Manmade Version of Somatostatin market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Manmade Version of Somatostatin Introduction
    1.2 World Manmade Version of Somatostatin Supply & Forecast
        1.2.1 World Manmade Version of Somatostatin Production Value (2019 & 2023 & 2030)
        1.2.2 World Manmade Version of Somatostatin Production (2019-2030)
        1.2.3 World Manmade Version of Somatostatin Pricing Trends (2019-2030)
    1.3 World Manmade Version of Somatostatin Production by Region (Based on Production Site)
        1.3.1 World Manmade Version of Somatostatin Production Value by Region (2019-2030)
        1.3.2 World Manmade Version of Somatostatin Production by Region (2019-2030)
        1.3.3 World Manmade Version of Somatostatin Average Price by Region (2019-2030)
        1.3.4 North America Manmade Version of Somatostatin Production (2019-2030)
        1.3.5 Europe Manmade Version of Somatostatin Production (2019-2030)
        1.3.6 China Manmade Version of Somatostatin Production (2019-2030)
        1.3.7 Japan Manmade Version of Somatostatin Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Manmade Version of Somatostatin Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Manmade Version of Somatostatin Major Market Trends

2 Demand Summary
    2.1 World Manmade Version of Somatostatin Demand (2019-2030)
    2.2 World Manmade Version of Somatostatin Consumption by Region
        2.2.1 World Manmade Version of Somatostatin Consumption by Region (2019-2024)
        2.2.2 World Manmade Version of Somatostatin Consumption Forecast by Region (2025-2030)
    2.3 United States Manmade Version of Somatostatin Consumption (2019-2030)
    2.4 China Manmade Version of Somatostatin Consumption (2019-2030)
    2.5 Europe Manmade Version of Somatostatin Consumption (2019-2030)
    2.6 Japan Manmade Version of Somatostatin Consumption (2019-2030)
    2.7 South Korea Manmade Version of Somatostatin Consumption (2019-2030)
    2.8 ASEAN Manmade Version of Somatostatin Consumption (2019-2030)
    2.9 India Manmade Version of Somatostatin Consumption (2019-2030)

3 World Manufacturers Competitive Analysis
    3.1 World Manmade Version of Somatostatin Production Value by Manufacturer (2019-2024)
    3.2 World Manmade Version of Somatostatin Production by Manufacturer (2019-2024)
    3.3 World Manmade Version of Somatostatin Average Price by Manufacturer (2019-2024)
    3.4 Manmade Version of Somatostatin Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Manmade Version of Somatostatin Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Manmade Version of Somatostatin in 2023
        3.5.3 Global Concentration Ratios (CR8) for Manmade Version of Somatostatin in 2023
    3.6 Manmade Version of Somatostatin Market: Overall Company Footprint Analysis
        3.6.1 Manmade Version of Somatostatin Market: Region Footprint
        3.6.2 Manmade Version of Somatostatin Market: Company Product Type Footprint
        3.6.3 Manmade Version of Somatostatin Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Manmade Version of Somatostatin Production Value Comparison
        4.1.1 United States VS China: Manmade Version of Somatostatin Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Manmade Version of Somatostatin Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Manmade Version of Somatostatin Production Comparison
        4.2.1 United States VS China: Manmade Version of Somatostatin Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Manmade Version of Somatostatin Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Manmade Version of Somatostatin Consumption Comparison
        4.3.1 United States VS China: Manmade Version of Somatostatin Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Manmade Version of Somatostatin Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Manmade Version of Somatostatin Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Manmade Version of Somatostatin Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Manmade Version of Somatostatin Production (2019-2024)
    4.5 China Based Manmade Version of Somatostatin Manufacturers and Market Share
        4.5.1 China Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Manmade Version of Somatostatin Production Value (2019-2024)
        4.5.3 China Based Manufacturers Manmade Version of Somatostatin Production (2019-2024)
    4.6 Rest of World Based Manmade Version of Somatostatin Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Manmade Version of Somatostatin Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Manmade Version of Somatostatin Production (2019-2024)

5 Market Analysis by Type
    5.1 World Manmade Version of Somatostatin Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Octreotide
        5.2.2 Lanreotide
        5.2.3 Pasireotide
        5.2.4 Other
    5.3 Market Segment by Type
        5.3.1 World Manmade Version of Somatostatin Production by Type (2019-2030)
        5.3.2 World Manmade Version of Somatostatin Production Value by Type (2019-2030)
        5.3.3 World Manmade Version of Somatostatin Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Manmade Version of Somatostatin Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Neuroendocrine Tumors
        6.2.2 Acromegaly
        6.2.3 Cushing Syndrome
        6.2.4 Other
    6.3 Market Segment by Application
        6.3.1 World Manmade Version of Somatostatin Production by Application (2019-2030)
        6.3.2 World Manmade Version of Somatostatin Production Value by Application (2019-2030)
        6.3.3 World Manmade Version of Somatostatin Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Details
        7.1.2 Novartis Major Business
        7.1.3 Novartis Manmade Version of Somatostatin Product and Services
        7.1.4 Novartis Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Novartis Recent Developments/Updates
        7.1.6 Novartis Competitive Strengths & Weaknesses
    7.2 Ipsen
        7.2.1 Ipsen Details
        7.2.2 Ipsen Major Business
        7.2.3 Ipsen Manmade Version of Somatostatin Product and Services
        7.2.4 Ipsen Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Ipsen Recent Developments/Updates
        7.2.6 Ipsen Competitive Strengths & Weaknesses
    7.3 Recordati Rare Diseases
        7.3.1 Recordati Rare Diseases Details
        7.3.2 Recordati Rare Diseases Major Business
        7.3.3 Recordati Rare Diseases Manmade Version of Somatostatin Product and Services
        7.3.4 Recordati Rare Diseases Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 Recordati Rare Diseases Recent Developments/Updates
        7.3.6 Recordati Rare Diseases Competitive Strengths & Weaknesses
    7.4 Chiesi Farmaceutici S.p.A
        7.4.1 Chiesi Farmaceutici S.p.A Details
        7.4.2 Chiesi Farmaceutici S.p.A Major Business
        7.4.3 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product and Services
        7.4.4 Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Chiesi Farmaceutici S.p.A Recent Developments/Updates
        7.4.6 Chiesi Farmaceutici S.p.A Competitive Strengths & Weaknesses
    7.5 Advanz Pharma
        7.5.1 Advanz Pharma Details
        7.5.2 Advanz Pharma Major Business
        7.5.3 Advanz Pharma Manmade Version of Somatostatin Product and Services
        7.5.4 Advanz Pharma Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Advanz Pharma Recent Developments/Updates
        7.5.6 Advanz Pharma Competitive Strengths & Weaknesses
    7.6 Cipla
        7.6.1 Cipla Details
        7.6.2 Cipla Major Business
        7.6.3 Cipla Manmade Version of Somatostatin Product and Services
        7.6.4 Cipla Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Cipla Recent Developments/Updates
        7.6.6 Cipla Competitive Strengths & Weaknesses
    7.7 Teva
        7.7.1 Teva Details
        7.7.2 Teva Major Business
        7.7.3 Teva Manmade Version of Somatostatin Product and Services
        7.7.4 Teva Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.7.5 Teva Recent Developments/Updates
        7.7.6 Teva Competitive Strengths & Weaknesses
    7.8 Gland Pharma
        7.8.1 Gland Pharma Details
        7.8.2 Gland Pharma Major Business
        7.8.3 Gland Pharma Manmade Version of Somatostatin Product and Services
        7.8.4 Gland Pharma Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.8.5 Gland Pharma Recent Developments/Updates
        7.8.6 Gland Pharma Competitive Strengths & Weaknesses
    7.9 Heritage Pharmaceuticals
        7.9.1 Heritage Pharmaceuticals Details
        7.9.2 Heritage Pharmaceuticals Major Business
        7.9.3 Heritage Pharmaceuticals Manmade Version of Somatostatin Product and Services
        7.9.4 Heritage Pharmaceuticals Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.9.5 Heritage Pharmaceuticals Recent Developments/Updates
        7.9.6 Heritage Pharmaceuticals Competitive Strengths & Weaknesses
    7.10 Sagent Pharmaceuticals
        7.10.1 Sagent Pharmaceuticals Details
        7.10.2 Sagent Pharmaceuticals Major Business
        7.10.3 Sagent Pharmaceuticals Manmade Version of Somatostatin Product and Services
        7.10.4 Sagent Pharmaceuticals Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.10.5 Sagent Pharmaceuticals Recent Developments/Updates
        7.10.6 Sagent Pharmaceuticals Competitive Strengths & Weaknesses
    7.11 Sun Pharmaceutical
        7.11.1 Sun Pharmaceutical Details
        7.11.2 Sun Pharmaceutical Major Business
        7.11.3 Sun Pharmaceutical Manmade Version of Somatostatin Product and Services
        7.11.4 Sun Pharmaceutical Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.11.5 Sun Pharmaceutical Recent Developments/Updates
        7.11.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
    7.12 Fresenius Kabi
        7.12.1 Fresenius Kabi Details
        7.12.2 Fresenius Kabi Major Business
        7.12.3 Fresenius Kabi Manmade Version of Somatostatin Product and Services
        7.12.4 Fresenius Kabi Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.12.5 Fresenius Kabi Recent Developments/Updates
        7.12.6 Fresenius Kabi Competitive Strengths & Weaknesses
    7.13 Mylan
        7.13.1 Mylan Details
        7.13.2 Mylan Major Business
        7.13.3 Mylan Manmade Version of Somatostatin Product and Services
        7.13.4 Mylan Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.13.5 Mylan Recent Developments/Updates
        7.13.6 Mylan Competitive Strengths & Weaknesses
    7.14 West-Ward Pharmaceuticals
        7.14.1 West-Ward Pharmaceuticals Details
        7.14.2 West-Ward Pharmaceuticals Major Business
        7.14.3 West-Ward Pharmaceuticals Manmade Version of Somatostatin Product and Services
        7.14.4 West-Ward Pharmaceuticals Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.14.5 West-Ward Pharmaceuticals Recent Developments/Updates
        7.14.6 West-Ward Pharmaceuticals Competitive Strengths & Weaknesses
    7.15 Suzhou Tianma Pharmaceutical
        7.15.1 Suzhou Tianma Pharmaceutical Details
        7.15.2 Suzhou Tianma Pharmaceutical Major Business
        7.15.3 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product and Services
        7.15.4 Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.15.5 Suzhou Tianma Pharmaceutical Recent Developments/Updates
        7.15.6 Suzhou Tianma Pharmaceutical Competitive Strengths & Weaknesses
    7.16 Sihuan Pharmaceutical
        7.16.1 Sihuan Pharmaceutical Details
        7.16.2 Sihuan Pharmaceutical Major Business
        7.16.3 Sihuan Pharmaceutical Manmade Version of Somatostatin Product and Services
        7.16.4 Sihuan Pharmaceutical Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.16.5 Sihuan Pharmaceutical Recent Developments/Updates
        7.16.6 Sihuan Pharmaceutical Competitive Strengths & Weaknesses
    7.17 Chengdu Tiantaishan pharmaceutical
        7.17.1 Chengdu Tiantaishan pharmaceutical Details
        7.17.2 Chengdu Tiantaishan pharmaceutical Major Business
        7.17.3 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product and Services
        7.17.4 Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.17.5 Chengdu Tiantaishan pharmaceutical Recent Developments/Updates
        7.17.6 Chengdu Tiantaishan pharmaceutical Competitive Strengths & Weaknesses
    7.18 Hybio Pharmaceutical
        7.18.1 Hybio Pharmaceutical Details
        7.18.2 Hybio Pharmaceutical Major Business
        7.18.3 Hybio Pharmaceutical Manmade Version of Somatostatin Product and Services
        7.18.4 Hybio Pharmaceutical Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.18.5 Hybio Pharmaceutical Recent Developments/Updates
        7.18.6 Hybio Pharmaceutical Competitive Strengths & Weaknesses
    7.19 Hainan Shuangcheng Pharmaceuticals
        7.19.1 Hainan Shuangcheng Pharmaceuticals Details
        7.19.2 Hainan Shuangcheng Pharmaceuticals Major Business
        7.19.3 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product and Services
        7.19.4 Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.19.5 Hainan Shuangcheng Pharmaceuticals Recent Developments/Updates
        7.19.6 Hainan Shuangcheng Pharmaceuticals Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Manmade Version of Somatostatin Industry Chain
    8.2 Manmade Version of Somatostatin Upstream Analysis
        8.2.1 Manmade Version of Somatostatin Core Raw Materials
        8.2.2 Main Manufacturers of Manmade Version of Somatostatin Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Manmade Version of Somatostatin Production Mode
    8.6 Manmade Version of Somatostatin Procurement Model
    8.7 Manmade Version of Somatostatin Industry Sales Model and Sales Channels
        8.7.1 Manmade Version of Somatostatin Sales Model
        8.7.2 Manmade Version of Somatostatin Typical Distributors

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. World Manmade Version of Somatostatin Production Value by Region (2019, 2023 and 2030) & (USD Million)
 Table 2. World Manmade Version of Somatostatin Production Value by Region (2019-2024) & (USD Million)
 Table 3. World Manmade Version of Somatostatin Production Value by Region (2025-2030) & (USD Million)
 Table 4. World Manmade Version of Somatostatin Production Value Market Share by Region (2019-2024)
 Table 5. World Manmade Version of Somatostatin Production Value Market Share by Region (2025-2030)
 Table 6. World Manmade Version of Somatostatin Production by Region (2019-2024) & (K Units)
 Table 7. World Manmade Version of Somatostatin Production by Region (2025-2030) & (K Units)
 Table 8. World Manmade Version of Somatostatin Production Market Share by Region (2019-2024)
 Table 9. World Manmade Version of Somatostatin Production Market Share by Region (2025-2030)
 Table 10. World Manmade Version of Somatostatin Average Price by Region (2019-2024) & (US$/Unit)
 Table 11. World Manmade Version of Somatostatin Average Price by Region (2025-2030) & (US$/Unit)
 Table 12. Manmade Version of Somatostatin Major Market Trends
 Table 13. World Manmade Version of Somatostatin Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
 Table 14. World Manmade Version of Somatostatin Consumption by Region (2019-2024) & (K Units)
 Table 15. World Manmade Version of Somatostatin Consumption Forecast by Region (2025-2030) & (K Units)
 Table 16. World Manmade Version of Somatostatin Production Value by Manufacturer (2019-2024) & (USD Million)
 Table 17. Production Value Market Share of Key Manmade Version of Somatostatin Producers in 2023
 Table 18. World Manmade Version of Somatostatin Production by Manufacturer (2019-2024) & (K Units)
 Table 19. Production Market Share of Key Manmade Version of Somatostatin Producers in 2023
 Table 20. World Manmade Version of Somatostatin Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 21. Global Manmade Version of Somatostatin Company Evaluation Quadrant
 Table 22. World Manmade Version of Somatostatin Industry Rank of Major Manufacturers, Based on Production Value in 2023
 Table 23. Head Office and Manmade Version of Somatostatin Production Site of Key Manufacturer
 Table 24. Manmade Version of Somatostatin Market: Company Product Type Footprint
 Table 25. Manmade Version of Somatostatin Market: Company Product Application Footprint
 Table 26. Manmade Version of Somatostatin Competitive Factors
 Table 27. Manmade Version of Somatostatin New Entrant and Capacity Expansion Plans
 Table 28. Manmade Version of Somatostatin Mergers & Acquisitions Activity
 Table 29. United States VS China Manmade Version of Somatostatin Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
 Table 30. United States VS China Manmade Version of Somatostatin Production Comparison, (2019 & 2023 & 2030) & (K Units)
 Table 31. United States VS China Manmade Version of Somatostatin Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
 Table 32. United States Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (States, Country)
 Table 33. United States Based Manufacturers Manmade Version of Somatostatin Production Value, (2019-2024) & (USD Million)
 Table 34. United States Based Manufacturers Manmade Version of Somatostatin Production Value Market Share (2019-2024)
 Table 35. United States Based Manufacturers Manmade Version of Somatostatin Production (2019-2024) & (K Units)
 Table 36. United States Based Manufacturers Manmade Version of Somatostatin Production Market Share (2019-2024)
 Table 37. China Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (Province, Country)
 Table 38. China Based Manufacturers Manmade Version of Somatostatin Production Value, (2019-2024) & (USD Million)
 Table 39. China Based Manufacturers Manmade Version of Somatostatin Production Value Market Share (2019-2024)
 Table 40. China Based Manufacturers Manmade Version of Somatostatin Production, (2019-2024) & (K Units)
 Table 41. China Based Manufacturers Manmade Version of Somatostatin Production Market Share (2019-2024)
 Table 42. Rest of World Based Manmade Version of Somatostatin Manufacturers, Headquarters and Production Site (State, Country)
 Table 43. Rest of World Based Manufacturers Manmade Version of Somatostatin Production Value, (2019-2024) & (USD Million)
 Table 44. Rest of World Based Manufacturers Manmade Version of Somatostatin Production Value Market Share (2019-2024)
 Table 45. Rest of World Based Manufacturers Manmade Version of Somatostatin Production, (2019-2024) & (K Units)
 Table 46. Rest of World Based Manufacturers Manmade Version of Somatostatin Production Market Share (2019-2024)
 Table 47. World Manmade Version of Somatostatin Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 48. World Manmade Version of Somatostatin Production by Type (2019-2024) & (K Units)
 Table 49. World Manmade Version of Somatostatin Production by Type (2025-2030) & (K Units)
 Table 50. World Manmade Version of Somatostatin Production Value by Type (2019-2024) & (USD Million)
 Table 51. World Manmade Version of Somatostatin Production Value by Type (2025-2030) & (USD Million)
 Table 52. World Manmade Version of Somatostatin Average Price by Type (2019-2024) & (US$/Unit)
 Table 53. World Manmade Version of Somatostatin Average Price by Type (2025-2030) & (US$/Unit)
 Table 54. World Manmade Version of Somatostatin Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 55. World Manmade Version of Somatostatin Production by Application (2019-2024) & (K Units)
 Table 56. World Manmade Version of Somatostatin Production by Application (2025-2030) & (K Units)
 Table 57. World Manmade Version of Somatostatin Production Value by Application (2019-2024) & (USD Million)
 Table 58. World Manmade Version of Somatostatin Production Value by Application (2025-2030) & (USD Million)
 Table 59. World Manmade Version of Somatostatin Average Price by Application (2019-2024) & (US$/Unit)
 Table 60. World Manmade Version of Somatostatin Average Price by Application (2025-2030) & (US$/Unit)
 Table 61. Novartis Basic Information, Manufacturing Base and Competitors
 Table 62. Novartis Major Business
 Table 63. Novartis Manmade Version of Somatostatin Product and Services
 Table 64. Novartis Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 65. Novartis Recent Developments/Updates
 Table 66. Novartis Competitive Strengths & Weaknesses
 Table 67. Ipsen Basic Information, Manufacturing Base and Competitors
 Table 68. Ipsen Major Business
 Table 69. Ipsen Manmade Version of Somatostatin Product and Services
 Table 70. Ipsen Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 71. Ipsen Recent Developments/Updates
 Table 72. Ipsen Competitive Strengths & Weaknesses
 Table 73. Recordati Rare Diseases Basic Information, Manufacturing Base and Competitors
 Table 74. Recordati Rare Diseases Major Business
 Table 75. Recordati Rare Diseases Manmade Version of Somatostatin Product and Services
 Table 76. Recordati Rare Diseases Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 77. Recordati Rare Diseases Recent Developments/Updates
 Table 78. Recordati Rare Diseases Competitive Strengths & Weaknesses
 Table 79. Chiesi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
 Table 80. Chiesi Farmaceutici S.p.A Major Business
 Table 81. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Product and Services
 Table 82. Chiesi Farmaceutici S.p.A Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 83. Chiesi Farmaceutici S.p.A Recent Developments/Updates
 Table 84. Chiesi Farmaceutici S.p.A Competitive Strengths & Weaknesses
 Table 85. Advanz Pharma Basic Information, Manufacturing Base and Competitors
 Table 86. Advanz Pharma Major Business
 Table 87. Advanz Pharma Manmade Version of Somatostatin Product and Services
 Table 88. Advanz Pharma Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 89. Advanz Pharma Recent Developments/Updates
 Table 90. Advanz Pharma Competitive Strengths & Weaknesses
 Table 91. Cipla Basic Information, Manufacturing Base and Competitors
 Table 92. Cipla Major Business
 Table 93. Cipla Manmade Version of Somatostatin Product and Services
 Table 94. Cipla Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 95. Cipla Recent Developments/Updates
 Table 96. Cipla Competitive Strengths & Weaknesses
 Table 97. Teva Basic Information, Manufacturing Base and Competitors
 Table 98. Teva Major Business
 Table 99. Teva Manmade Version of Somatostatin Product and Services
 Table 100. Teva Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 101. Teva Recent Developments/Updates
 Table 102. Teva Competitive Strengths & Weaknesses
 Table 103. Gland Pharma Basic Information, Manufacturing Base and Competitors
 Table 104. Gland Pharma Major Business
 Table 105. Gland Pharma Manmade Version of Somatostatin Product and Services
 Table 106. Gland Pharma Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 107. Gland Pharma Recent Developments/Updates
 Table 108. Gland Pharma Competitive Strengths & Weaknesses
 Table 109. Heritage Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 110. Heritage Pharmaceuticals Major Business
 Table 111. Heritage Pharmaceuticals Manmade Version of Somatostatin Product and Services
 Table 112. Heritage Pharmaceuticals Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 113. Heritage Pharmaceuticals Recent Developments/Updates
 Table 114. Heritage Pharmaceuticals Competitive Strengths & Weaknesses
 Table 115. Sagent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 116. Sagent Pharmaceuticals Major Business
 Table 117. Sagent Pharmaceuticals Manmade Version of Somatostatin Product and Services
 Table 118. Sagent Pharmaceuticals Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 119. Sagent Pharmaceuticals Recent Developments/Updates
 Table 120. Sagent Pharmaceuticals Competitive Strengths & Weaknesses
 Table 121. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 122. Sun Pharmaceutical Major Business
 Table 123. Sun Pharmaceutical Manmade Version of Somatostatin Product and Services
 Table 124. Sun Pharmaceutical Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 125. Sun Pharmaceutical Recent Developments/Updates
 Table 126. Sun Pharmaceutical Competitive Strengths & Weaknesses
 Table 127. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
 Table 128. Fresenius Kabi Major Business
 Table 129. Fresenius Kabi Manmade Version of Somatostatin Product and Services
 Table 130. Fresenius Kabi Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 131. Fresenius Kabi Recent Developments/Updates
 Table 132. Fresenius Kabi Competitive Strengths & Weaknesses
 Table 133. Mylan Basic Information, Manufacturing Base and Competitors
 Table 134. Mylan Major Business
 Table 135. Mylan Manmade Version of Somatostatin Product and Services
 Table 136. Mylan Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 137. Mylan Recent Developments/Updates
 Table 138. Mylan Competitive Strengths & Weaknesses
 Table 139. West-Ward Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 140. West-Ward Pharmaceuticals Major Business
 Table 141. West-Ward Pharmaceuticals Manmade Version of Somatostatin Product and Services
 Table 142. West-Ward Pharmaceuticals Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 143. West-Ward Pharmaceuticals Recent Developments/Updates
 Table 144. West-Ward Pharmaceuticals Competitive Strengths & Weaknesses
 Table 145. Suzhou Tianma Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 146. Suzhou Tianma Pharmaceutical Major Business
 Table 147. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Product and Services
 Table 148. Suzhou Tianma Pharmaceutical Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 149. Suzhou Tianma Pharmaceutical Recent Developments/Updates
 Table 150. Suzhou Tianma Pharmaceutical Competitive Strengths & Weaknesses
 Table 151. Sihuan Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 152. Sihuan Pharmaceutical Major Business
 Table 153. Sihuan Pharmaceutical Manmade Version of Somatostatin Product and Services
 Table 154. Sihuan Pharmaceutical Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 155. Sihuan Pharmaceutical Recent Developments/Updates
 Table 156. Sihuan Pharmaceutical Competitive Strengths & Weaknesses
 Table 157. Chengdu Tiantaishan pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 158. Chengdu Tiantaishan pharmaceutical Major Business
 Table 159. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Product and Services
 Table 160. Chengdu Tiantaishan pharmaceutical Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 161. Chengdu Tiantaishan pharmaceutical Recent Developments/Updates
 Table 162. Chengdu Tiantaishan pharmaceutical Competitive Strengths & Weaknesses
 Table 163. Hybio Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 164. Hybio Pharmaceutical Major Business
 Table 165. Hybio Pharmaceutical Manmade Version of Somatostatin Product and Services
 Table 166. Hybio Pharmaceutical Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 167. Hybio Pharmaceutical Recent Developments/Updates
 Table 168. Hybio Pharmaceutical Competitive Strengths & Weaknesses
 Table 169. Hainan Shuangcheng Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 170. Hainan Shuangcheng Pharmaceuticals Major Business
 Table 171. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Product and Services
 Table 172. Hainan Shuangcheng Pharmaceuticals Manmade Version of Somatostatin Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
 Table 173. Hainan Shuangcheng Pharmaceuticals Recent Developments/Updates
 Table 174. Hainan Shuangcheng Pharmaceuticals Competitive Strengths & Weaknesses
 Table 175. Global Key Players of Manmade Version of Somatostatin Upstream (Raw Materials)
 Table 176. Global Manmade Version of Somatostatin Typical Customers
 Table 177. Manmade Version of Somatostatin Typical Distributors


List of Figures
 Figure 1. Manmade Version of Somatostatin Picture
 Figure 2. World Manmade Version of Somatostatin Production Value: 2019 & 2023 & 2030, (USD Million)
 Figure 3. World Manmade Version of Somatostatin Production Value and Forecast (2019-2030) & (USD Million)
 Figure 4. World Manmade Version of Somatostatin Production (2019-2030) & (K Units)
 Figure 5. World Manmade Version of Somatostatin Average Price (2019-2030) & (US$/Unit)
 Figure 6. World Manmade Version of Somatostatin Production Value Market Share by Region (2019-2030)
 Figure 7. World Manmade Version of Somatostatin Production Market Share by Region (2019-2030)
 Figure 8. North America Manmade Version of Somatostatin Production (2019-2030) & (K Units)
 Figure 9. Europe Manmade Version of Somatostatin Production (2019-2030) & (K Units)
 Figure 10. China Manmade Version of Somatostatin Production (2019-2030) & (K Units)
 Figure 11. Japan Manmade Version of Somatostatin Production (2019-2030) & (K Units)
 Figure 12. Manmade Version of Somatostatin Market Drivers
 Figure 13. Factors Affecting Demand
 Figure 14. World Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 15. World Manmade Version of Somatostatin Consumption Market Share by Region (2019-2030)
 Figure 16. United States Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 17. China Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 18. Europe Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 19. Japan Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 20. South Korea Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 21. ASEAN Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 22. India Manmade Version of Somatostatin Consumption (2019-2030) & (K Units)
 Figure 23. Producer Shipments of Manmade Version of Somatostatin by Manufacturer Revenue ($MM) and Market Share (%): 2023
 Figure 24. Global Four-firm Concentration Ratios (CR4) for Manmade Version of Somatostatin Markets in 2023
 Figure 25. Global Four-firm Concentration Ratios (CR8) for Manmade Version of Somatostatin Markets in 2023
 Figure 26. United States VS China: Manmade Version of Somatostatin Production Value Market Share Comparison (2019 & 2023 & 2030)
 Figure 27. United States VS China: Manmade Version of Somatostatin Production Market Share Comparison (2019 & 2023 & 2030)
 Figure 28. United States VS China: Manmade Version of Somatostatin Consumption Market Share Comparison (2019 & 2023 & 2030)
 Figure 29. United States Based Manufacturers Manmade Version of Somatostatin Production Market Share 2023
 Figure 30. China Based Manufacturers Manmade Version of Somatostatin Production Market Share 2023
 Figure 31. Rest of World Based Manufacturers Manmade Version of Somatostatin Production Market Share 2023
 Figure 32. World Manmade Version of Somatostatin Production Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 33. World Manmade Version of Somatostatin Production Value Market Share by Type in 2023
 Figure 34. Octreotide
 Figure 35. Lanreotide
 Figure 36. Pasireotide
 Figure 37. Other
 Figure 38. World Manmade Version of Somatostatin Production Market Share by Type (2019-2030)
 Figure 39. World Manmade Version of Somatostatin Production Value Market Share by Type (2019-2030)
 Figure 40. World Manmade Version of Somatostatin Average Price by Type (2019-2030) & (US$/Unit)
 Figure 41. World Manmade Version of Somatostatin Production Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 42. World Manmade Version of Somatostatin Production Value Market Share by Application in 2023
 Figure 43. Neuroendocrine Tumors
 Figure 44. Acromegaly
 Figure 45. Cushing Syndrome
 Figure 46. Other
 Figure 47. World Manmade Version of Somatostatin Production Market Share by Application (2019-2030)
 Figure 48. World Manmade Version of Somatostatin Production Value Market Share by Application (2019-2030)
 Figure 49. World Manmade Version of Somatostatin Average Price by Application (2019-2030) & (US$/Unit)
 Figure 50. Manmade Version of Somatostatin Industry Chain
 Figure 51. Manmade Version of Somatostatin Procurement Model
 Figure 52. Manmade Version of Somatostatin Sales Model
 Figure 53. Manmade Version of Somatostatin Sales Channels, Direct Sales, and Distribution
 Figure 54. Methodology
 Figure 55. Research Process and Data Source

Companies Mentioned

Novartis
Ipsen
Recordati Rare Diseases
Chiesi Farmaceutici S.p.A
Advanz Pharma
Cipla
Teva
Gland Pharma
Heritage Pharmaceuticals
Sagent Pharmaceuticals
Sun Pharmaceutical
Fresenius Kabi
Mylan
West-Ward Pharmaceuticals
Suzhou Tianma Pharmaceutical
Sihuan Pharmaceutical
Chengdu Tiantaishan pharmaceutical
Hybio Pharmaceutical
Hainan Shuangcheng Pharmaceuticals